Haresh Jhangiani, MD
Hematology-Oncology · Fountain Valley, CANPI 1578566998
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.9%. Among hematology-oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,037 payments — averaging $37.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$8K
- Incyte Corporation$7K
- Gilead$7K
- Coherus Oncology, Inc.$6K
- AstraZeneca$5K
- Bristol Myers Squibb$4K
- plus $39K from 54 others
Across 150 payments — averaging $4478.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$183K
- Takeda Pharmaceuticals U.S.A., Inc.$98K
- Hexal AG$50K
- Otsuka Pharmaceutical Co., Ltd.$47K
- EMD Serono, Inc.$46K
- Acerta Pharma LLC$39K
- plus $208K from 19 others
What the payments were for
- Consulting fees$28,09537%
- Speaking & faculty fees$4,1105%
- Travel & lodging$2,5393%
- Food & beverage$40,58853%
- Education$1,4252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,757 in reported general payments places this provider in the 90th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 32 | $444,076 |
| PomalystPomalidomide | 16 | $362,326 |
| EnhertuFam-Trastuzumab Deruxtecn-Nxki | 21 | $223,978 |
| Lupron DepotLeuprolide Acetate | 40 | $201,441 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 13 | $122,179 |
| KisqaliRibociclib Succinate | 11 | $82,433 |
| ZarxioFilgrastim-Sndz | 53 | $67,993 |
| ProcritEpoetin Alfa | 18 | $67,292 |
| XgevaDenosumab | 14 | $44,434 |
| TrazimeraTrastuzumab-Qyyp | 14 | $42,694 |
| Abiraterone Acetate | 15 | $24,492 |
| Fosaprepitant Dimeglumine | 37 | $3,800 |
| Paclitaxel | 22 | $2,346 |
| Letrozole | 101 | $2,124 |
| Fulvestrant | 13 | $1,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $922 | $444,07632 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,487 | $362,32616 claims |
| Daiichi Sankyo Inc.Enhertu | $735 | $223,97821 claims |
| AbbVieLupron Depot | $806 | $201,44140 claims |
| NovartisKisqali | $2,616 | $82,43311 claims |
| Johnson & JohnsonProcrit | $3,717 | $67,29218 claims |
| AmgenXgeva | $1,190 | $44,43414 claims |
| PfizerTrazimera | $3,910 | $42,69414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in Fountain Valley
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Mark ScholzMarina del Rey$62K
- Bertrand TuanSan Francisco$45K
- Brian ChoiRiverside$35K
- Shawn ShambaughBakersfield$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.